SCHEMBL1734441

SCHEMBL1734441

CN(C)C(=O)c1cc(-c2ccccc2)nc(N(C)c2ccco2)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.46
NPC1 O15118 4/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 2/20 0.43
DAGLA Q9Y4D2 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
POLB P06746 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA1 P30542 1/20 0.35
TSHR P16473 1/20 0.34
ABCB1 P08183 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1735687 0.86 KDM4E (0.43) RAB9ANPC1KMT2AKDM4ESMN1; SMN2
SCHEMBL1734520 0.76 KDM4E (0.74) RAB9AKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL1734442 0.74 ALDH1A1 (0.49) RAB9ANPC1KMT2AKDM4ESMN1; SMN2
SCHEMBL14510332 0.72 ADORA2A (0.56) RAB9ANPC1KMT2AKDM4ESMN1; SMN2
SCHEMBL1733562 0.69 KDM4E (0.59) RAB9AKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL1734460 0.68 KDM4E (0.51) RAB9AKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL1734250 0.67 KDM4E (0.72) KMT2AKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL1938476 0.67 KMO (0.68) RAB9AKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL3662260 0.66 AXL (0.36) RAB9ANPC1KMT2AKDM4ESMN1; SMN2
SCHEMBL930311 0.66 ADORA2A (0.58) ADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 RAB9A 1846/4885NPC1 52/4885KMT2A 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.